Landos Biopharma, Inc. Common Stock
LABP
LABP was delisted on the 23rd of May, 2024.
33 hedge funds and large institutions have $261M invested in Landos Biopharma, Inc. Common Stock in 2021 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 11 increasing their positions, 9 reducing their positions, and 15 closing their positions.
22% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 9
19% more capital invested
Capital invested by funds: $219M → $261M (+$42.6M)
30% less funds holding
Funds holding: 47 → 33 (-14)
93% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 15
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LGM
Logos Global Management
San Francisco,
California
|
+$1.84M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.3M |
| 3 |
State Street
Boston,
Massachusetts
|
+$482K |
| 4 |
BlackRock
New York
|
+$421K |
| 5 |
AI
ArchPoint Investors
Coral Gables,
Florida
|
+$282K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
-$4.33M |
| 2 |
MIM
Monashee Investment Management
Boston,
Massachusetts
|
-$879K |
| 3 |
ZP
Zimmer Partners
New York
|
-$868K |
| 4 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$674K |
| 5 |
Tudor Investment Corp
Stamford,
Connecticut
|
-$492K |
LABP Hedge Fund Activity: Q2 2021 in Review
33 of the 5,746 institutional investors tracked by Wall St. Rank reported a position in Landos Biopharma, Inc. Common Stock (LABP) for Q2 2021, worth a combined $261M — up 19% from $219M a quarter earlier.
Sellers outnumbered buyers: 15 funds closed out of LABP and 1 opened new positions — a net loss of 14 holders — while 9 trimmed existing stakes and 11 added.
The largest buyer was Logos Global Management, adding an estimated $1.84M. The largest seller was Deerfield Management, exiting entirely with an estimated $4.33M sold.
- 33 institutional investors held Landos Biopharma, Inc. Common Stock (LABP) as of Q2 2021, down from 47 in Q1 2021.
- Funds reported $261M of Landos Biopharma, Inc. Common Stock stock for Q2 2021, up 19% quarter-over-quarter.
- 1 fund opened new Landos Biopharma, Inc. Common Stock positions in Q2 2021 and 15 closed out, a net change of -14 holders.
- The largest Landos Biopharma, Inc. Common Stock buyer in Q2 2021 was Logos Global Management, an estimated $1.84M added.
- The largest Landos Biopharma, Inc. Common Stock seller in Q2 2021 was Deerfield Management, an estimated $4.33M sold.
Based on aggregated 13F filings for Q2 2021.